2 recherche sur le tag 'DRUG-Therapy'   

Design of hybrid molecules for drug development / Decker, Michael

Public ISBD Titre : Design of hybrid molecules for drug development Type de document : texte imprimé Auteurs : Decker, Michael, Éditeur scientifique Editeur : Amsterdam : Elsevier Année de publication : 2017 Importance : xiii, 338 p. ISBN/ISSN/EAN : 978-0-08-101011-2 Note générale : Highlights an approach unimpaired by the limitations of the classical search for lead structures - one of the core problems in modern drug development processes, making the content of high relevance for both academic and non-academic drug development processes Pulls together research and design techniques in a novel way to give researchers the best possible platform from which to review the approaches and techniques applied Compares the advantages and disadvantages of these compounds Includes the very latest developments, such as photoactivatable and photo-responsive drugs Langues : Anglais (eng) Catégories : Biochimie Tags : METALS-THERAPEUTIC USE  DRUG-THERAPY  CANCER DRUG  MOLECULAR BIOLOGY Index. décimale : B-F Résumé : Design of Hybrid Molecules for Drug Development reviews the principles, advantages, and limitations involved with designing these groundbreaking compounds. Beginning with an introduction to hybrid molecule design and background as to their need, the book goes on to explore a range of important hybrids, with hybrids containing natural products, molecules containing NO- and H2S-donors, dual-acting compounds acting as receptor ligands and enzyme inhibitors, and the design of photoresponsive drugs all discussed. Drawing on practical case studies, the hybridization of molecules for development as treatments for a number of key diseases is then outlined, including the design of hybrids for Alzheimer's, cancer, and malaria. With its cutting-edge reviews of breaking developments in this exciting field, the book offers a novel approach for all those working in the design, development, and administration of drugs for a range of debilitating disorders. Note de contenu : " * Multitarget-Directed Antioxidants as Therapeutic Agents: Putting the Focus on the Oxidative Stress * Towards Gaseous Mediator Hybrid Drugs * Designed Hybrid Compounds for Tropical Parasitic Diseases * Dual-Acting Compounds Acting as Receptor Ligands and Enzyme Inhibitors * Multitarget Anti-Alzheimer Hybrid Compounds: Do They Work In Vivo? * Anticancer Hybrids * Molecular Hybridization: An Emerging Tool for the Design of Novel Therapeutics for Alzheimer’s Disease * Computational Methods in Multitarget Drug Discovery * Medicinal Chemistry of Hybrids for Neurodegenerative Diseases * Photoresponsive Hybrid Compounds". Cote : B-F050 Num_Inv : 3511 Localisation : LCC (SdS) Design of hybrid molecules for drug development [texte imprimé] / Decker, Michael, Éditeur scientifique . - Amsterdam : Elsevier, 2017 . - xiii, 338 p. ISBN : 978-0-08-101011-2 Highlights an approach unimpaired by the limitations of the classical search for lead structures - one of the core problems in modern drug development processes, making the content of high relevance for both academic and non-academic drug development processes Pulls together research and design techniques in a novel way to give researchers the best possible platform from which to review the approaches and techniques applied Compares the advantages and disadvantages of these compounds Includes the very latest developments, such as photoactivatable and photo-responsive drugs Langues : Anglais (eng) Catégories : Biochimie Tags : METALS-THERAPEUTIC USE  DRUG-THERAPY  CANCER DRUG  MOLECULAR BIOLOGY Index. décimale : B-F Résumé : Design of Hybrid Molecules for Drug Development reviews the principles, advantages, and limitations involved with designing these groundbreaking compounds. Beginning with an introduction to hybrid molecule design and background as to their need, the book goes on to explore a range of important hybrids, with hybrids containing natural products, molecules containing NO- and H2S-donors, dual-acting compounds acting as receptor ligands and enzyme inhibitors, and the design of photoresponsive drugs all discussed. Drawing on practical case studies, the hybridization of molecules for development as treatments for a number of key diseases is then outlined, including the design of hybrids for Alzheimer's, cancer, and malaria. With its cutting-edge reviews of breaking developments in this exciting field, the book offers a novel approach for all those working in the design, development, and administration of drugs for a range of debilitating disorders. Note de contenu : " * Multitarget-Directed Antioxidants as Therapeutic Agents: Putting the Focus on the Oxidative Stress * Towards Gaseous Mediator Hybrid Drugs * Designed Hybrid Compounds for Tropical Parasitic Diseases * Dual-Acting Compounds Acting as Receptor Ligands and Enzyme Inhibitors * Multitarget Anti-Alzheimer Hybrid Compounds: Do They Work In Vivo? * Anticancer Hybrids * Molecular Hybridization: An Emerging Tool for the Design of Novel Therapeutics for Alzheimer’s Disease * Computational Methods in Multitarget Drug Discovery * Medicinal Chemistry of Hybrids for Neurodegenerative Diseases * Photoresponsive Hybrid Compounds". Cote : B-F050 Num_Inv : 3511 Localisation : LCC (SdS)

Exemplaires(1)

Code-barres	Cote	Support	Localisation	Section	Disponibilité
3511	B-F050	Texte imprimé	Bibliothèque	Livre	Disponible

DNA and RNA cleavers and chemotherapy of cancer and viral diseases / Bernard Meunier

Public ISBD Titre : DNA and RNA cleavers and chemotherapy of cancer and viral diseases Type de document : texte imprimé Auteurs : Bernard Meunier, Éditeur scientifique Editeur : Boston : Kluwer Academic Publishers Année de publication : 1996 Importance : xxv, 372 p. ISBN/ISSN/EAN : 978-0-7923-4025-6 Langues : Anglais (eng) Catégories : Biochimie Tags : DNA RNA-Cleaves  DRUG-Therapy  Ribonucleases-Congress Index. décimale : B-F Résumé : "Recently, there has been an increase of interest in the discovery and design of drugs that cleave DNA and RNA with sequence specificity. This class of compounds can be used as therapeutic agents, especially in the treatment of cancer and viral diseases. Novel mechanisms have also been discovered, allowing such agents to be used as tools in the study of the structure and function of nucleic acids. The major advances have been achieved with enediyne antibiotics and their synthetic analogues, bleomycin-metal complexes, metal-drug complexes, ribozymes and their mimics, and antisense and antigene oligonucleotides. This study discusses DNA cleavage by enediyne molecules, the mechanism of action of bleomycin, the paradigm of DNA cleavers site-specific DNA and RNA cleavage and its mechanism, RNA cleavage by RNase H, RNA hydrolysis by ribozymes and metal complexes, and redox regulation of the human immunodeficiency virus." Cote : B-F027 (SdS) Num_Inv : 1624 DNA and RNA cleavers and chemotherapy of cancer and viral diseases [texte imprimé] / Bernard Meunier, Éditeur scientifique . - Boston : Kluwer Academic Publishers, 1996 . - xxv, 372 p. ISBN : 978-0-7923-4025-6 Langues : Anglais (eng) Catégories : Biochimie Tags : DNA RNA-Cleaves  DRUG-Therapy  Ribonucleases-Congress Index. décimale : B-F Résumé : "Recently, there has been an increase of interest in the discovery and design of drugs that cleave DNA and RNA with sequence specificity. This class of compounds can be used as therapeutic agents, especially in the treatment of cancer and viral diseases. Novel mechanisms have also been discovered, allowing such agents to be used as tools in the study of the structure and function of nucleic acids. The major advances have been achieved with enediyne antibiotics and their synthetic analogues, bleomycin-metal complexes, metal-drug complexes, ribozymes and their mimics, and antisense and antigene oligonucleotides. This study discusses DNA cleavage by enediyne molecules, the mechanism of action of bleomycin, the paradigm of DNA cleavers site-specific DNA and RNA cleavage and its mechanism, RNA cleavage by RNase H, RNA hydrolysis by ribozymes and metal complexes, and redox regulation of the human immunodeficiency virus." Cote : B-F027 (SdS) Num_Inv : 1624

Exemplaires(1)

Code-barres	Cote	Support	Localisation	Section	Disponibilité
1624	B-F027	Texte imprimé	Bibliothèque	Livre	Disponible